Alkem Laboratories announces a COPD awareness campaign that focuses on promoting healthy lungs and the role of inhalation therapy. The campaign spans the country, aiming to educate the public and ensure efforts against respiratory diseases.
Chronic Obstructive Pulmonary Disease (COPD) affects approximately 391 million individuals globally, contributing to breathlessness and chronic cough. With three million annual fatalities, COPD stands among the leading global causes of death. The aging population and exposure to risk factors propel its progression, primarily linked to tobacco, smoke, and inhaled toxic particles.
“Campaign’s focus on early lung health value, expanding horizons for COPD prevention. Recent COPD research reveals factors beyond tobacco smoking, leading to new opportunities for early diagnosis and treatment of precursor conditions like pre-COPD and PRISm,” Sudipto Roy, President, Head-Acute Business, Alkem Laboratories, said.
Globally, efforts to combat COPD include smoking-cessation programmes, addressing air pollution, and examining childhood disadvantage factors. Alkem’s claims to be involved in advocating for quality healthcare access, pointing out inhalation therapy’s importance as a fundamental right.
The campaign urges employers to create safe breathing environments, citizens to promote air cleanliness, and supports research for improved care access. Telehealth, routine pulmonary function screenings, and spirometry use as a general health marker are pointed out throughout all life stages.